Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors Post published:February 22, 2021 Post category:Press Release
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform Post published:February 18, 2021 Post category:Press Release
Mind Cure Comments on Recent Promotional Activity Post published:February 17, 2021 Post category:Press Release
MINDCURE’s Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization Post published:February 16, 2021 Post category:Press Release
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option Post published:February 10, 2021 Post category:Press Release
MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category Post published:January 26, 2021 Post category:Press Release
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering Post published:January 22, 2021 Post category:Press Release
Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering Post published:January 21, 2021 Post category:Press Release
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy Post published:January 12, 2021 Post category:Press Release